Denosumab has shown to be noninferior to zoledronic acid for the prevention of skeletal-related events and provides an alternative .
Fewer adverse events related to renal toxicity have been noted with denosumab compared with zoledronic acid and may be preferred in this setting .
Purpose To up date guideline recommendations on the role of bone-modifying agents in multiple myeloma .
A multicenter, randomized clinical trial comparing zoledronic acid versus observation in patients with asymptomatic myeloma
Bisphosphonates ( BPs ) are effective in the prevention and treatment of skeletal‐related events ( SREs ) in patients with symptomatic myeloma who are receiving chemotherapy . Recent data also suggest a possible antineoplastic activity of BPs . Few studies published to date have explored the role of BPs in patients with untreated , asymptomatic myeloma ( AM ) . No data are available on the efficacy of zoledronic acid in these patients
Denosumab has shown to be noninferior to zoledronic acid for the prevention of skeletal-related events and provides an alternative .
Fewer adverse events related to renal toxicity have been noted with denosumab compared with zoledronic acid and may be preferred in this setting .
Purpose To up date guideline recommendations on the role of bone-modifying agents in multiple myeloma .